IP Library Granted Patent US 8,097,255
Granted Patent B2
US 8,097,255 · App. 13/021,445 · Granted Jan 17, 2012

Mammalian receptor protein DCRS5; methods of treatment

Assignee: Schering Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,255
App. No.
13/021,445
Granted
Jan 17, 2012
Kind
B2
Abstract

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (9)

1. A method of treating a human subject experiencing an inflammatory bowel disorder (IBD) comprising administering an effective amount of an antagonist antibody that specifically binds to a polypeptide comprising residues 1-606 of SEQ ID NO: 2, or an antigen binding fragment.

2. The method of claim 1 , wherein the IBD is Crohn's disease.

3. The method of claim 2 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody or antigen binding fragment thereof.

4. The method of claim 2 , wherein the antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof.

5. The method of claim 2 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′) 2 fragment.

6. The method of claim 1 , wherein the IBD is ulcerative colitis.

7. The method of claim 6 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody or antigen binding fragment thereof.

8. The method of claim 6 , wherein the antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof.

9. The method of claim 6 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′) 2 fragment.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
Continuity (7)
Continuation 12834728 · Jul 12, 2010
Continuation 12181152 · Jul 28, 2008
Continuation 10720026 · Nov 21, 2003
Continuation In Part 10667290 · Sep 18, 2003
Division 09853180 · May 10, 2001
Provisional Application 60203426 · May 10, 2000
Related Publication 20110129465A1 · Jun 2, 2011